<DOC>
	<DOCNO>NCT02114242</DOCNO>
	<brief_summary>Parkinson disease ( PD ) , multiple system atrophy ( MSA ) progressive supranuclear palsy ( PSP ) neurodegenerative disorder . PD MSA alpha-synucleinopathies , characterize abnormal accumulation alpha-synuclein , tau protein accumulate PSP . The development biological marker diagnosis prognosis PD , MSA PSP remain unmet need . Such biological marker crucial future disease-modification neuroprotection trial . Alpha-synuclein high potential biomarker development since constitutes pathological hallmark feature PD MSA . The oligomeric alpha-synuclein seem particularly involve abnormal protein aggregation alpha-synucleinopathies . The main objective compare oligomeric alpha-synuclein CSF level PD , MSA PSP patient . PD MSA patient receive Cerebrospinal Fluid ( CSF ) blood sample two study visit ( baseline 12 month ) . Major secondary objective ( ) assess potential association biomarker clinical measure disease severity progression MSA PSP , ( ii ) ass variation biomarker correlation disease severity progression PD , MSA PSP .</brief_summary>
	<brief_title>Biomarkers Parkinsonian Syndromes</brief_title>
	<detailed_description>The differential diagnosis Parkinson 's disease , multiple system atrophy progressive supranuclear palsy difficult early disease . PD , MSA PSP neurodegenerative disorder . PD MSA belong alpha-synucleinopathies , characterize abnormal accumulation alpha-synuclein . Alpha-synuclein accumulate intraneuronal Lewy body PD patient intracytoplasmic glial inclusion MSA . In PSP , tau protein accumulate neuron glia cell alpha-synuclein deposit find small extend . The development biological marker diagnosis prognosis PD , MSA PSP remain unmet need . Beyond guide clinical decision-making , biological marker crucial future disease-modification neuroprotection trial . Alpha-synuclein high potential biomarker development since constitutes pathological hallmark feature PD MSA . The oligomeric alpha-synuclein fraction whose CSF level increase PD seem particularly involve abnormal protein aggregation alpha-synucleinopathies . The main objective study compare oligomeric alpha-synuclein CSF level PD , MSA PSP patient . Secondary objective ( ) compare total alpha-synuclein level index total/oligomeric alpha-synuclein PD , MSA PSP , ( ii ) study correlation concordance CSF plasma level total oligomeric alpha-synuclein , ( iii ) ass potential association biomarker clinical measure disease severity progression ( iv ) ass variation biomarker time correlation disease severity progression .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>PD patient inclusion criterion : Patients suffer PD accord clinical criterion ( Hughes et al , 1992 ) Written informed consent Patient cover national health system exclusion criterion : Patient tutelage patient cover national health system MSA patient inclusion criterion : Patients suffer `` probable '' MSA accord clinical consensus criterion ( Gilman et al , 2008 ) , age &gt; 30 Written informed consent Patient cover national health system exclusion criterion : UMSARS IV score &gt; 4 point Patient tutelage PSP patient inclusion criterion : Patients suffer PSP accord NNIPPS trial criterion ( Bensimon et al. , 2009 ) , age &gt; 40 Written informed consent Patient cover national health system exclusion criterion : PSPRS item 26 score &gt; 3 point Patient tutelage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>multiple system atrophy</keyword>
	<keyword>progressive supranuclear palsy</keyword>
	<keyword>alpha-synuclein</keyword>
</DOC>